Soumya D. Chakravarty

72888 APEX: Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis by Participant Baseline Characteristics

Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier et autres

98 SAFETY OF GUSELKUMAB IN PATIENTS AGED ≥60 YEARS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES: A POOLED ANALYSIS OF REGISTRATIONAL TRIALS IN UC, CD, PSA AND PSO

Adam S. Faye, Shaji Sebastian, Victoria McCaffrey, Ivana Bravatà et autres

98 SAFETY OF GUSELKUMAB IN PATIENTS AGED ≥60 YEARS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES: A POOLED ANALYSIS OF REGISTRATIONAL TRIALS IN UC, CD, PSA AND PSO

Adam S. Faye, Shaji Sebastian, Victoria McCaffrey, Ivana Bravatà et autres

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Alexis Ogdie, J F Merola, P. Mease, Christopher T Ritchlin et autres

OBJECTIVE: To evaluate the efficacy and safety of guselkumab, an interleukin-23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor. METHODS: In SOLSTICE (phase 3b, randomized, multicenter, …

us, il (code pays fourni par la source)

Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors

Philip J. Mease, Jessica A. Walsh, Timothy Fitzgerald, Soumya D. Chakravarty et autres

INTRODUCTION: Patients with active psoriatic arthritis (PsA) initiating guselkumab are nearly two times more likely to remain persistent with on-label therapy at 12 months compared to those initiating subcutaneous (SC) interleukin-17A inhibitors (IL-17Ai). In this real-world study, on-label treatment persistence at 24 …

us (code pays fourni par la source)

On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors

Philip J. Mease, Jessica A. Walsh, Timothy Fitzgerald, Soumya D. Chakravarty et autres

INTRODUCTION: There is limited prior literature comparing long-term treatment persistence between guselkumab and subcutaneous (SC) tumor necrosis factor inhibitors (TNFi) in biologic-naïve and biologic-experienced patients with active psoriatic arthritis (PsA). This study compared on-label persistence through 24 months between patients with active …

us (code pays fourni par la source)

204 Inhibition of Structural Damage Progression With Guselkumab, a Selective IL-23i, in Participants With Active PsA: Results Through Week 24 of the Phase 3b APEX Study

Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier et autres

us, gb, ca, nl (code pays fourni par la source)

331 Durable Inhibition of Structural Damage Progression and Improvements in Joint Disease Activity With Guselkumab in Active and Erosive Psoriatic Arthritis: Week 48 Results From APEX

Christopher T. Ritchlin, Philip J. Mease, Laura C. Coates, Alexa P. Kollmeier et autres

us, gb, ca, nl (code pays fourni par la source)

Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data

Herta Crauwels, Sarah Ringold, Samantha Howard, Bart van Hartingsveldt et autres

BACKGROUND: Psoriatic arthritis (PsA) and juvenile PsA (jPsA) are chronic inflammatory diseases with similar features that differ by age and sequence of symptom onset. PsA and psoriasis (PsO) share comparable pathology across ages, with interleukin (IL)-23 as a key mediator. Prior to …

us, gb, nl (code pays fourni par la source)

S1663 Inhibition of Structural Damage Progression With Guselkumab in Participants With Active Psoriatic Arthritis: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study

Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier et autres

Introduction: Extraintestinal manifestations(EIMs), eg, joint involvement and psoriatic arthritis (PsA), are common in pts with IBD and may be associated with more severe IBD. Guselkumab (GUS), a dual-acting IL-23p19 subunit inhibitor, is approved to treat CD, UC, PsA, and psoriasis. No studies …

Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study

Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier et autres

OBJECTIVES: The APEX study evaluated the effects of guselkumab, a fully human, dual-acting monoclonal antibody able to bind CD64 and selectively inhibit the interleukin (IL)-23p19 subunit, on clinical and radiographic outcomes in active psoriatic arthritis (PsA). METHODS: APEX (ongoing, phase 3b, double-blind, …

us, gb, ca, nl (code pays fourni par la source)

ABS1075 ON-LABEL PERSISTENCE THROUGH 24 MONTHS IN PATIENTS WITH PSORIATIC ARTHRITIS USING GUSELKUMAB OR SUBCUTANEOUS INTERLEUKIN-17A INHIBITORS

Philip J. Mease, J. A. Walsh, Timothy Fitzgerald, Soumya D. Chakravarty et autres